Xconomy National

Archives

by in
Entry Author Date Location
Onyx Drug Effective in New Myeloma Patients, Taking Aim at Millennium Luke Timmerman 12/12/11 San Francisco
Epigenetic Drug Startup Tensha Therapeutics Snags $15M Series A Erin Kutz 09/12/11 Boston
Seattle Genetics: The Next Litmus Test for High Priced Cancer Drugs Luke Timmerman 08/22/11 National
Xconomist of the Week: Tony Coles’ Journey from Mass General Doctor to SF Biotech CEO Luke Timmerman 08/18/11 National
Onyx Unveils Results for Myeloma Drug, Raising Stakes in Rivalry with Millennium Luke Timmerman 12/07/10 San Francisco
Glaxo Ends Resveratrol Drug Study Ryan McBride 12/01/10 Boston
Onyx Delays Cancer Drug Application as FDA Asks for More Data on Manufacturing Luke Timmerman 10/07/10 San Francisco
Onyx Pockets $59M Upfront From Japanese Partner, to Market Myeloma Drugs Luke Timmerman 09/08/10 San Francisco
LS9 Reveals Key Biofuel Genes, Onyx Drug Passes Big Trial, Solazyme Seeks First-Mover Edge, & More Bay Area Life Sciences News Luke Timmerman 07/30/10 San Francisco
Onyx Preps for Dash to FDA, After Myeloma Drug Helps Sickest of the Sick Luke Timmerman 07/26/10 San Francisco
Oncothyreon Stock Plummets as Side Effect Emerges in Cancer Patient, Trials Halted Luke Timmerman 03/23/10 Seattle
Roche Scraps Partnership With Seattle Genetics on Lymphoma Drug Luke Timmerman 12/11/09 Seattle
How Millennium Is Tapping A Harvard Lab to Help Discover New Cancer Drugs Ryan McBride 11/24/09 Boston
Acceleron, Bucking Conventional Wisdom, Pushes Ahead Drug For Bone Loss, Anemia Luke Timmerman 09/11/09 Boston
$252M Potential in CLDA and CombinatoRx Deal Ryan McBride 08/13/09 Boston
Biotech Startup Acetylon Pharma Catches $7.25M in A Round from Backers Such As New England Patriots Owner Ryan McBride 08/07/09 Boston
Genzyme’s Mozobil Gets European Approval Ryan McBride 08/05/09 Boston
Genzyme Wins FDA Approval of Mozobil Luke Timmerman 12/15/08 Boston
Blood News: A Quick Rundown of Headlines From the American Society of Hematology Luke Timmerman 12/09/08 National
Millennium’s Velcade, As Time Wears On, Shows Durable Ability to Prolong Lives Luke Timmerman 12/08/08 Boston
Biogen Turns Down Dying Patient’s Request For Tysabri—and Explains Why Luke Timmerman 10/14/08 Boston
Biogen Idec, Elan Start First Cancer Trial With Tysabri Luke Timmerman 09/05/08 Boston
Page 1 of 1
    

Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.

© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.

Site produced by Andrew Koyfman with design from Rob Hunter.